Formulations

Formulations
Product Description

We understand that speed is of the essence when working to deliver a life-changing drug to market. Our experienced clinical formulation development team can support formulation development across a vast range of dosage forms – including oral, ophthalmic and transdermal formulations, as well as injectables, inhaled therapies and more. Whether NCE or 505(b)(2), we can work with our partners to help you rapidly progress your drug from the preclinical stage through to commercial formulation development as part of an integrated process.

Benefits of formulation development with Nanoform

Our rigorous QbD approach to the formulation development of nanoformed drugs can open up new possibilities for drug delivery innovation. Reducing the API’s size down to the nanoscale can enable:

Reproducibly fast dissolution

High drug load

Potential for a simple formulation with less excipients

High physical suspension stability

Enhanced permeability

Novel opportunities for exploring coformulations, in particular dual API formulations

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other

More Products from Nanoform Finland Oy (3)

  • AI Drug Candidate Screening

    Product AI Drug Candidate Screening

    Our STARMAP® 2.0 platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered nanoforming and that exhibit optimal production characteristics.

    When existing data alone is not sufficient for generating specific pr...
  • Biologics

    Product Biologics

    Why have we developed our bio nanoparticle technology?

    The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes,...
  • Small Molecules

    Product Small Molecules

    Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.

    CESS® is a bottom-up method of recrystallization that wo...

Nanoform Finland Oy resources (3)

  • Brochure Nanoform launches next-generation STARMAP ®️ v2.0, the AI-based drug candidate selection tool for CESS ®️

    The technology utilizes sparse-data AI to augment experimental results from its CESS®️ nanoparticle engineering process with detailed expert knowledge, allowing reliable predictions to be made regarding partners’ potential success of nanoforming their drug molecules.
  • Whitepaper Transforming drug development with nanoparticle engineering

    This white paper delves into current technological innovations in nanoparticle engineering that aim to increase the number of drugs reaching the market.
  • Video Overcoming Drug Development Challenges with Nanotechnology

    This webinar originally aired as part of CPHI Discover - 17-28 May 2021 This session will focus on the application of nanotechnology to drug development, examining several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics. Gain perspective on the current status and the future growth and success of the field. New promising nanotechnology platforms to overcome drug development challenges to rapidly progress novel drugs to market. Specific applications of emerging interest in nanotechnology-based drug development systems The potential impact of Nanotechnology on the development of Personalized Medicine Increasing the possibilities and probabilities for Pharma using STARMAP AI technology Frontrunners within the particle engineering space - CESS® vs the rest Positive data from the first-in-human trial of a Nano-formed drug